Developer docs
API playgroundTry for free, no card

Search company profiles

Longeveron

Full company profile

uuid00004f3

Namestring
Longeveron
Legal namestring
Longeveron Inc.
Websiteurl
longeveron.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company founded in 2014 and headquartered in Miami, Florida, that develops allogeneic mesenchymal stem cell (MSC) therapies for rare pediatric and aging-related conditions. Its lead and only clinical candidate, Lomecel-B (laromestrocel), is a living-cell product manufactured from bone-marrow-derived MSCs of young healthy adult donors, culture-expanded into billions of cells and cryopreserved in single-dose vials (e.g., 50 million cells per dose). The company is evaluating this single product across four distinct indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty, pursuing a "pipeline in a product" strategy. The platform is supported by 33 issued global patents, proprietary potency assay methodologies, and five FDA designations across programs.

The company is pre-revenue and generates no material product sales; it finances operations through dilutive equity raises. Since 2023 it has executed multiple registered direct offerings and private placements totaling approximately $51 million, most recently a $30 million private placement in March 2026 led by Coastlands Capital with Janus Henderson Investors, Logos Capital, and Kalehua Capital, extending cash runway into Q4 2026. Management has explicitly repositioned toward an asset-light operating model targeting licensing and co-development partnerships across all four indications, presenting at BIO 2026, JPM Healthcare Week, and the CVCT Forum in pursuit of strategic partners. Material value catalysts include the Q3 2026 topline ELPIS II Phase 2b readout in HLHS, a potential Rare Pediatric Disease Priority Review Voucher (recently reauthorized through 2029) worth an estimated $150–200 million on BLA approval, and EMA SME status granted in June 2026 to support European marketing authorization.

Longeveron's competitive position rests on a combination of regulatory designations (Orphan Drug, Fast Track, Rare Pediatric Disease, RMAT, EMA SME), peer-reviewed clinical publications in Nature Medicine and Cell Stem Cell, and scientific leadership anchored by co-founder Dr. Joshua Hare. The company faces a near-term regulatory inflection: a March 2026 FDA Type C meeting concluded that the current primary endpoint of right ventricle ejection fraction in the ELPIS II trial is insufficient to demonstrate efficacy and the agency will no longer refer to the trial as pivotal. Leadership has undergone significant turnover, with Stephen H. Willard appointed permanent CEO in February 2026 following interim CEO Than Powell and the departure of Wa'el Hashad in September 2025, while Dr. Hare remains Executive Chairman and CSO.

Short descriptiontext

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing a single allogeneic mesenchymal stem cell therapy, Lomecel-B (laromestrocel), evaluated across four indications including Hypoplastic Left Heart Syndrome, Alzheimer's disease, Pediatric Dilated Cardiomyopathy, and aging-related frailty, and is repositioning toward an asset-light licensing model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, mesenchymal stem cells, regenerative medicine, biopharmaceutical development, rare disease therapeutics
Industry4 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy / Regenerative Medicine Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Partnership Agreements
TypeLicensing Royalties
Description

Longeveron is pursuing strategic licensing partnerships for its stem cell therapy programs across multiple indications. Upon successful clinical trials and regulatory approval, the company would generate revenue through licensing deals, co-development partnerships, and potential product sales.

stocktitan.net
2Priority Review Voucher
TypeLicensing Royalties
Description

Upon BLA approval for Hypoplastic Left Heart Syndrome, Longeveron may be eligible to receive a Rare Pediatric Disease Priority Review Voucher, which can be sold for $150-200 million each.

biospace.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Lomecel-B
Description

Proprietary allogeneic mesenchymal stem cell therapy (laromestrocel) being evaluated in multiple indications including HLHS, PDCM, Alzheimer's disease, and Age-Related Frailty.

longeveron.com
Core offering1 text field

Longeveron is a clinical-stage biotechnology company developing Lomecel-B (laromestrocel), a proprietary allogeneic mesenchymal stem cell (MSC) therapy isolated from bone marrow of healthy young adult donors, culture-expanded into billions of cells and frozen in doses (e.g., 50 million cells). The therapy is being evaluated across four indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty, with the company pursuing a licensing/partnership-based commercialization model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 63.4-meter improvement in 6-minute walk test at 9 months for age-related frailty patients (p=0.0077)
+4 more records
Product overview1 text field

Longeveron is a clinical-stage biotechnology company developing a single unified therapeutic product, Lomecel-B (laromestrocel), which is a proprietary allogeneic mesenchymal stem cell therapy. The product is being evaluated across four distinct indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty. The company's development strategy positions laromestrocel as a 'pipeline in a product' approach, leveraging the same cellular therapy platform across multiple rare pediatric and aging-related conditions. The company operates with five FDA designations supporting various programs.

Product and service4 records
1Lomecel-B (laromestrocel)
CategoryCell Therapy / Allogeneic MSC Therapy
Description

A proprietary, scalable, allogeneic cellular therapy comprised of mesenchymal stem cells (MSCs) isolated from the bone marrow of healthy young adult donors. Laromestrocel is being evaluated across multiple indications including Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty. The cells are culture-expanded into billions, harvested into doses (e.g., 50 million cells), and frozen for future administration to patients.

2ELPIS II (Phase 2b HLHS Clinical Trial Program)
CategoryClinical Development Program
Description

Pivotal Phase 2b clinical trial program evaluating laromestrocel as a potential adjunct therapy for Hypoplastic Left Heart Syndrome (HLHS) in pediatric patients. Trial enrolled 40 patients at 12 leading U.S. pediatric cardiac centers in collaboration with the National Heart, Lung, and Blood Institute. Top-line data anticipated in Q3 2026.

3CLEAR MIND (Phase 2a Alzheimer's Clinical Trial Program)
CategoryClinical Development Program
Description

Phase 2a randomized controlled clinical trial evaluating laromestrocel in mild Alzheimer's disease. Phase 2a results were published in Nature Medicine in March 2025, and additional data analysis was accepted for poster presentation at AAIC 2026.

4Pediatric Dilated Cardiomyopathy (PDCM) Development Program
CategoryClinical Development Program
Description

Development program for laromestrocel targeting Pediatric Dilated Cardiomyopathy, a rare progressive heart disease affecting approximately 100,000 children worldwide with 40% mortality within two years of diagnosis. IND approved in 2025, with FDA confirming a single Phase 2b/3 study is required.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Selected as a StartUp Health Alzheimer's Disease Moonshot Company to participate in StartUp Health Apollo House during JPM Healthcare Week 2026, hosting meetings with investors and partners.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration through NIH grants for the ELPIS II Phase 2b trial. The trial enrolled 40 pediatric patients at 12 leading pediatric cardiac centers across the United States in collaboration with NHLBI.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage developer of allogeneic mesenchymal stem cell therapies (remestemcel-L) for inflammatory and cardiac conditions. Most direct peer to Longeveron in MSC platform, though Mesoblast is further along commercially with FDA-approved products.

TypeDirect peer
Description

Clinical-stage biotech developing cell therapies (CAP-1002, cardiosphere-derived cells) for Duchenne muscular dystrophy and cardiac indications. Comparable stage, size, and cardiac/rare disease focus to Longeveron.

3Pluristem Therapeutics
TypeDirect peer
Description

Developer of placenta-derived allogeneic cell therapies (PLX cells) for multiple indications including muscle injury and hematopoietic recovery. Comparable allogeneic platform model and indication breadth to Longeveron's pipeline approach.

TypeDirect peer
Description

Clinical-stage developer of autologous MSC-based therapies (NurOwn) for neurodegenerative diseases including ALS and MS. Direct peer in MSC platform and overlapping neurological indication space (Alzheimer's adjacent).

5Athersys / Healios K.K.
TypeDirect peer
Description

Developer of MultiStem allogeneic cell therapy platform for stroke, ARDS, and acute inflammatory conditions. Comparable allogeneic platform architecture and clinical-stage status to Longeveron's MSC approach.

TypeBroad incumbent
Description

Commercial-stage cell therapy company with FDA-approved autologous products (MACI, Epicel). Larger and more established than Longeveron; serves as a benchmark for cell therapy commercialization economics, though focused on autologous rather than allogeneic model.

TypeDirect peer
Description

Clinical-stage developer of allogeneic cell therapies for CNS, oncology, and rare diseases with pipeline-in-a-product strategy similar to Longeveron's approach. Comparable size and asset-light partnership orientation.

TypeDirect peer
Description

Clinical-stage developer of placenta-derived allogeneic cell therapies (PDA-002, NK cells) with focus on aging-related conditions and cancer. Highly comparable allogeneic platform and aging-frailty indication overlap with Longeveron.

TypeDirect peer
Description

Clinical-stage developer of cell-based therapies for cardiac indications (CardiAMP, CardiALLO) with focus on heart failure. Direct overlap with Longeveron's HLHS and PDCM cardiac programs.

TypeEmerging player
Description

Developer of adipose-derived regenerative cell therapies (ECCS-50/Celution) for scleroderma, osteoarthritis, and other indications. Comparable regenerative cell therapy approach though focused on adipose rather than bone marrow MSC source.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Longeveron

Cell Therapy / Regenerative Medicine Biopharmaceuticalslongeveron.com

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing a single allogeneic mesenchymal stem cell therapy, Lomecel-B (laromestrocel), evaluated across four indications including Hypoplastic Left Heart Syndrome, Alzheimer's disease, Pediatric Dilated Cardiomyopathy, and aging-related frailty, and is repositioning toward an asset-light licensing model.

What Longeveron does

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company founded in 2014 and headquartered in Miami, Florida, that develops allogeneic mesenchymal stem cell (MSC) therapies for rare pediatric and aging-related conditions. Its lead and only clinical candidate, Lomecel-B (laromestrocel), is a living-cell product manufactured from bone-marrow-derived MSCs of young healthy adult donors, culture-expanded into billions of cells and cryopreserved in single-dose vials (e.g., 50 million cells per dose). The company is evaluating this single product across four distinct indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty, pursuing a "pipeline in a product" strategy. The platform is supported by 33 issued global patents, proprietary potency assay methodologies, and five FDA designations across programs.

The company is pre-revenue and generates no material product sales; it finances operations through dilutive equity raises. Since 2023 it has executed multiple registered direct offerings and private placements totaling approximately $51 million, most recently a $30 million private placement in March 2026 led by Coastlands Capital with Janus Henderson Investors, Logos Capital, and Kalehua Capital, extending cash runway into Q4 2026. Management has explicitly repositioned toward an asset-light operating model targeting licensing and co-development partnerships across all four indications, presenting at BIO 2026, JPM Healthcare Week, and the CVCT Forum in pursuit of strategic partners. Material value catalysts include the Q3 2026 topline ELPIS II Phase 2b readout in HLHS, a potential Rare Pediatric Disease Priority Review Voucher (recently reauthorized through 2029) worth an estimated $150–200 million on BLA approval, and EMA SME status granted in June 2026 to support European marketing authorization.

Longeveron's competitive position rests on a combination of regulatory designations (Orphan Drug, Fast Track, Rare Pediatric Disease, RMAT, EMA SME), peer-reviewed clinical publications in Nature Medicine and Cell Stem Cell, and scientific leadership anchored by co-founder Dr. Joshua Hare. The company faces a near-term regulatory inflection: a March 2026 FDA Type C meeting concluded that the current primary endpoint of right ventricle ejection fraction in the ELPIS II trial is insufficient to demonstrate efficacy and the agency will no longer refer to the trial as pivotal. Leadership has undergone significant turnover, with Stephen H. Willard appointed permanent CEO in February 2026 following interim CEO Than Powell and the departure of Wa'el Hashad in September 2025, while Dr. Hare remains Executive Chairman and CSO.

Longeveron firmographics

Firmographics
Name
Longeveron
Legal name
Longeveron Inc.
Website
https://longeveron.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing a single allogeneic mesenchymal stem cell therapy, Lomecel-B (laromestrocel), evaluated across four indications including Hypoplastic Left Heart Syndrome, Alzheimer's disease, Pediatric Dilated Cardiomyopathy, and aging-related frailty, and is repositioning toward an asset-light licensing model.
Ownership category
akta.pro rank

Longeveron industry classification

Industry
Product category
Cell Therapy / Regenerative Medicine Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Allogeneic cell therapy
  • Mesenchymal stem cells
  • Regenerative medicine
  • Biopharmaceutical development
  • Rare disease therapeutics

Where Longeveron is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Longeveron business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing and Partnership Agreements: Longeveron is pursuing strategic licensing partnerships for its stem cell therapy programs across multiple indications. Upon successful clinical trials and regulatory approval, the company would generate revenue through licensing deals, co-development partnerships, and potential product sales.
  2. Priority Review Voucher: Upon BLA approval for Hypoplastic Left Heart Syndrome, Longeveron may be eligible to receive a Rare Pediatric Disease Priority Review Voucher, which can be sold for $150-200 million each.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Longeveron product offering

Product offering

Core offering

Longeveron is a clinical-stage biotechnology company developing Lomecel-B (laromestrocel), a proprietary allogeneic mesenchymal stem cell (MSC) therapy isolated from bone marrow of healthy young adult donors, culture-expanded into billions of cells and frozen in doses (e.g., 50 million cells). The therapy is being evaluated across four indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty, with the company pursuing a licensing/partnership-based commercialization model.

Product overview

Longeveron is a clinical-stage biotechnology company developing a single unified therapeutic product, Lomecel-B (laromestrocel), which is a proprietary allogeneic mesenchymal stem cell therapy. The product is being evaluated across four distinct indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty. The company's development strategy positions laromestrocel as a 'pipeline in a product' approach, leveraging the same cellular therapy platform across multiple rare pediatric and aging-related conditions. The company operates with five FDA designations supporting various programs.

Differentiator

Problem solved

Functional benefit

Brands

  • Lomecel-B: Proprietary allogeneic mesenchymal stem cell therapy (laromestrocel) being evaluated in multiple indications including HLHS, PDCM, Alzheimer's disease, and Age-Related Frailty.

Products and services

  • Lomecel-B (laromestrocel) A proprietary, scalable, allogeneic cellular therapy comprised of mesenchymal stem cells (MSCs) isolated from the bone marrow of healthy young adult donors. Laromestrocel is being evaluated across multiple indications including Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty. The cells are culture-expanded into billions, harvested into doses (e.g., 50 million cells), and frozen for future administration to patients.
  • ELPIS II (Phase 2b HLHS Clinical Trial Program) Pivotal Phase 2b clinical trial program evaluating laromestrocel as a potential adjunct therapy for Hypoplastic Left Heart Syndrome (HLHS) in pediatric patients. Trial enrolled 40 patients at 12 leading U.S. pediatric cardiac centers in collaboration with the National Heart, Lung, and Blood Institute. Top-line data anticipated in Q3 2026.
  • CLEAR MIND (Phase 2a Alzheimer's Clinical Trial Program) Phase 2a randomized controlled clinical trial evaluating laromestrocel in mild Alzheimer's disease. Phase 2a results were published in Nature Medicine in March 2025, and additional data analysis was accepted for poster presentation at AAIC 2026.
  • Pediatric Dilated Cardiomyopathy (PDCM) Development Program Development program for laromestrocel targeting Pediatric Dilated Cardiomyopathy, a rare progressive heart disease affecting approximately 100,000 children worldwide with 40% mortality within two years of diagnosis. IND approved in 2025, with FDA confirming a single Phase 2b/3 study is required.

Quantifiable outcome

  • 63.4-meter improvement in 6-minute walk test at 9 months for age-related frailty patients (p=0.0077)
  • +4 more outcomes

Companies that use Longeveron

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Longeveron technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Longeveron partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered supporting and core.

  • StartUp HealthsupportingStrategic or Co-development Partner · 1 December 2025Selected as a StartUp Health Alzheimer's Disease Moonshot Company to participate in StartUp Health Apollo House during JPM Healthcare Week 2026, hosting meetings with investors and partners.
  • National Heart, Lung, and Blood Institute (NHLBI)coreStrategic or Co-development PartnerClinical collaboration through NIH grants for the ELPIS II Phase 2b trial. The trial enrolled 40 pediatric patients at 12 leading pediatric cardiac centers across the United States in collaboration with NHLBI.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Longeveron competitors and assessment

Company assessment

Direct peers

  • Mesoblast: Commercial-stage developer of allogeneic mesenchymal stem cell therapies (remestemcel-L) for inflammatory and cardiac conditions. Most direct peer to Longeveron in MSC platform, though Mesoblast is further along commercially with FDA-approved products.
  • Capricor Therapeutics: Clinical-stage biotech developing cell therapies (CAP-1002, cardiosphere-derived cells) for Duchenne muscular dystrophy and cardiac indications. Comparable stage, size, and cardiac/rare disease focus to Longeveron.
  • Pluristem Therapeutics: Developer of placenta-derived allogeneic cell therapies (PLX cells) for multiple indications including muscle injury and hematopoietic recovery. Comparable allogeneic platform model and indication breadth to Longeveron's pipeline approach.
  • BrainStorm Cell Therapeutics: Clinical-stage developer of autologous MSC-based therapies (NurOwn) for neurodegenerative diseases including ALS and MS. Direct peer in MSC platform and overlapping neurological indication space (Alzheimer's adjacent).
  • Athersys / Healios K.K. Developer of MultiStem allogeneic cell therapy platform for stroke, ARDS, and acute inflammatory conditions. Comparable allogeneic platform architecture and clinical-stage status to Longeveron's MSC approach.
  • Lineage Cell Therapeutics: Clinical-stage developer of allogeneic cell therapies for CNS, oncology, and rare diseases with pipeline-in-a-product strategy similar to Longeveron's approach. Comparable size and asset-light partnership orientation.
  • Celularity Inc. Clinical-stage developer of placenta-derived allogeneic cell therapies (PDA-002, NK cells) with focus on aging-related conditions and cancer. Highly comparable allogeneic platform and aging-frailty indication overlap with Longeveron.
  • BioCardia, Inc. Clinical-stage developer of cell-based therapies for cardiac indications (CardiAMP, CardiALLO) with focus on heart failure. Direct overlap with Longeveron's HLHS and PDCM cardiac programs.

Broad incumbents

  • Vericel Corporation: Commercial-stage cell therapy company with FDA-approved autologous products (MACI, Epicel). Larger and more established than Longeveron; serves as a benchmark for cell therapy commercialization economics, though focused on autologous rather than allogeneic model.

Emerging players

  • Cytori Therapeutics: Developer of adipose-derived regenerative cell therapies (ECCS-50/Celution) for scleroderma, osteoarthritis, and other indications. Comparable regenerative cell therapy approach though focused on adipose rather than bone marrow MSC source.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Longeveron social profiles

Digital presence

Longeveron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Longeveron leadership team

Management profile

Number of profiles

Profiles11 records

Longeveron funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Longeveron M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longeveron

What does Longeveron do?

Longeveron is a clinical-stage biotechnology company developing Lomecel-B (laromestrocel), a proprietary allogeneic mesenchymal stem cell (MSC) therapy isolated from bone marrow of healthy young adult donors, culture-expanded into billions of cells and frozen in doses (e.g., 50 million cells). The therapy is being evaluated across four indications: Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer's disease, and Aging-related Frailty, with the company pursuing a licensing/partnership-based commercialization model.

Is Longeveron a public or private company?

Longeveron is a public company. It is classified as public and is currently operating.

When was Longeveron founded?

Longeveron was founded in 2014. It employs 11 to 50 people.

Where is Longeveron based?

Longeveron is headquartered in Miami, United States, in the North America region.

How does Longeveron make money?

Two revenue lines are on record. Licensing and Partnership Agreements are the primary driver. The others are priority Review Voucher.

Who are Longeveron's main competitors?

Direct peers on record are Mesoblast, Capricor Therapeutics, Pluristem Therapeutics, BrainStorm Cell Therapeutics, Athersys / Healios K.K., Lineage Cell Therapeutics, Celularity Inc. and BioCardia, Inc.. Vericel Corporation is listed as a broad incumbent. Cytori Therapeutics is listed as an emerging player.

Does Longeveron have an API?

No public API is recorded for Longeveron.

What industry is Longeveron in?

Longeveron's product category is Cell Therapy / Regenerative Medicine Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeLongeveron Reports Third-Quarter 2026 Results, Requests FDA Meeting Following ELPIS II Data and Reviews Strategic Alternatives | LGVN Stock NewsLongeveron reported a Q3 2026 net loss of $6.1 million and $7.2 million in cash, with its ELPIS II trial failing to meet the primary efficacy endpoint for HLHS. The company requested an FDA meeting and retained Lucid Capital Markets to explore strategic alternatives, including potential partnerships or mergers.Stock TitanLongeveron Q3 earnings: $6.1M loss, $7.2M cashLongeveron reported a Q3 2026 net loss of $6.1 million and $7.2 million in cash. The company requested an FDA meeting to review ELPIS II trial results and retained Lucid Capital Markets to explore strategic options, including a potential business combination.Business & FinancialBiotech Stock Longeveron Inc. (NASDAQ: LGVN) Makes Nasdaq Top Gainer List On NewsLongeveron Inc. announced a private placement with institutional investors for up to $30 million, led by Coastlands Capital, with an initial closing of about $15 million. The stock rose to $1.02, up $0.48, on volume over 141 million shares. Proceeds will fund operations into Q4 2026, past the Phase 2b ELPIS II trial readout.Quiver QuantitativeLongeveron Inc. Retains Lucid Capital Markets to Explore Strategic Alternatives, Including Potential Business Combination | LGVN Stock NewsLongeveron Inc. retained Lucid Capital Markets as financial advisor to explore strategic opportunities, including a potential business combination. The company's lead product, laromestrocel, has received multiple FDA designations, including Orphan Drug, Fast Track, and RMAT. The press release includes forward-looking statements about uncertainties in strategic options and product development.YahooLongeveron Announces Engagement of Lucid Capital MarketsLongeveron Inc. retained Lucid Capital Markets as its financial advisor to explore potential strategic opportunities, including a potential business combination. The company's lead product, laromestrocel, has received five FDA designations, including Orphan Drug and RMAT designations.Stock TitanLongeveron retains Lucid Capital as financial adviserLongeveron Inc. retained Lucid Capital Markets as its financial advisor to explore potential strategic opportunities, including a possible business combination. The company's lead product, laromestrocel, has received five FDA designations. No specific terms or timeline were disclosed.GlobeNewswireLongeveron Announces Engagement of Lucid Capital MarketsLongeveron Inc. retained Lucid Capital Markets as its financial advisor to explore potential strategic opportunities, including a possible business combination. The company's lead product, laromestrocel, has received five FDA designations, including Orphan Drug and RMAT designations.Longevity.TechnologyUpdated Phase 2b data show fewer major cardiac events in HLHSLongeveron released updated results from ELPIS II, a Phase 2b trial of Laromestrocel in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary endpoint, but the company reported a prespecified secondary endpoint of fewer major adverse cardiac events (eight in standard-of-care versus one in the Laromestrocel arm, P=0.043). The company plans to request a meeting with the FDA to discuss next steps.TradingViewLongeveron Reports Significant MACE Result in ELPIS II HLHS TrialLongeveron reported that laromestrocel was associated with fewer major adverse cardiac events than standard of care in its ELPIS II HLHS trial, though the trial missed its primary endpoint. The prespecified secondary MACE endpoint showed 8 events with standard of care versus 1 with laromestrocel (P=0.043), and no treatment-related serious adverse events were identified through 12 months. Longeveron plans to request an FDA meeting to discuss next steps.The future of tradingLongeveron’s laromestrocel shows fewer major adverse cardiac events in Phase 2b trialLongeveron reported updated ELPIS II Phase 2b results showing laromestrocel significantly reduced major adverse cardiac events in infants with hypoplastic left heart syndrome. The trial previously failed its primary goal of improving right ventricular pumping function at 12 months, but laromestrocel showed favorable safety through 12 months with no treatment-related serious adverse events. The company plans to request an FDA meeting to review results and determine potential next steps.